What this page establishes
- FDA placed BPC-157 on the Category 2 bulk substances list under section 503A, citing possible immunogenicity risk, peptide-related impurities and insufficient safety data.
- FDA updated its Category 2 list effective 22 April 2026, removing 12 substances after the nominators withdrew their nominations, including BPC-157, TB-500, MOTS-c, injectable GHK-Cu, Melanotan II, Semax and PEG-MGF.
- A PCAC recommendation for inclusion is not an approval and does not by itself make a peptide legal to sell or use.
- BPC-157's research literature concerns tissue repair and gastrointestinal protection; it is not a weight-loss agent and no trial supports weight-loss use.
Quick answers
I want it for a tendon injury, not weight loss. Does the healing research hold up?
The interesting work is mostly in animals, and the human literature is thinner by a wide margin.
Read the full answer
FDA's stated concerns were possible immunogenicity, peptide-related impurities and insufficient safety data, and no published human programme has closed those gaps. It is a tissue-repair candidate at a preclinical stage rather than a treatment with a human evidence base.Why was ulcerative colitis the indication on the Federal Register notice?
That is what the substance was put in front of the committee for, and it reflects what was nominated rather than what has been shown.
Read the full answer
A nomination is a request to consider a substance for a compounding list, not a finding that it treats the condition named. The outcome of that meeting is not confirmed here.I have already been taking it. What should I do?
Tell a clinician, including the source and how long. There is no approved human use anywhere as of 23 August 2026, which means no monitoring guidance exists and no one has characterised what to watch for.
Read the full answer
Immunogenicity in particular is not something a person can detect themselves.
BPC-157 does not cause weight loss, and no trial supports using it for that. Its research literature concerns tissue repair and gastrointestinal protection, which is a different question entirely. It appears on weight-loss peptide lists because it draws heavy search traffic from the injury-recovery world, and listicles are built around traffic. The genuinely interesting thing about BPC-157 in 2026 is regulatory: its US compounding position moved in April and was put on an advisory committee agenda in July, and it still holds no approval anywhere.
What BPC-157 is
BPC-157 is a synthetic pentadecapeptide, a fifteen-amino-acid chain derived from a sequence found in a human gastric protein. The research interest in it comes from animal work on wound healing, tendon and ligament repair, and protection of the gastrointestinal lining.
That is the whole scope of the scientific case. It is a tissue-repair and GI-protection candidate, at a preclinical stage, and the honest summary is that the animal literature is more extensive than the human literature by a wide margin.
It is not a weight-loss compound
No trial supports weight-loss use of BPC-157. Its literature does not concern body weight or fat mass as endpoints, which means there is no positive evidence and no negative evidence, just an absence.
Its presence in weight-loss peptide roundups is a marketing artefact rather than a scientific claim. BPC-157 has search volume, weight-loss peptide has search volume, and content that combines them performs. Neither the compound nor its research literature has anything to do with the category it gets listed in.
Human evidence
Human safety data are thin. FDA's stated concerns when it placed BPC-157 on the Category 2 bulk substances list were possible immunogenicity, peptide-related impurities, and insufficient safety data. Those are the specific gaps, and none has been closed by a published human programme.
Immunogenicity is worth understanding rather than skipping past. A peptide can provoke an immune response against itself, and in some cases against a related endogenous protein. That risk only shows up in properly monitored human studies, and it is not something a user can detect.
The FDA Category 2 designation
FDA placed BPC-157 in Category 2 of the bulk drug substances list under section 503A of the Federal Food, Drug, and Cosmetic Act. Category 2 identifies substances with significant safety risks, and its practical effect was to put BPC-157 outside the substances that compounding pharmacies could use.
A Category 2 listing is not a ban on the molecule in the abstract. It is a determination about compounding. The distinction matters because both sides of the argument tend to overstate it.
April 2026: removal from Category 2
FDA updated its Category 2 list effective 22 April 2026, removing twelve substances after the nominators withdrew their nominations. BPC-157 was on that list, alongside TB-500, MOTS-c, injectable GHK-Cu, Melanotan II, Semax and PEG-MGF.
Removal from Category 2 following withdrawn nominations is a procedural outcome. It is not a safety finding, not a reversal of FDA's stated concerns, and not an approval. The substance did not become legal to sell for human use because a nomination was withdrawn.
July 2026: the scheduled PCAC review
FDA scheduled a Pharmacy Compounding Advisory Committee meeting for 23 July 2026 to consider BPC-157 free base and BPC-157 acetate for possible inclusion on the 503A Bulks List, which is the list of substances compounding pharmacies may use. The Federal Register notice put the substance in front of the committee for ulcerative colitis, not for weight loss or tissue repair. Whether the meeting went ahead as noticed, and what the committee concluded, is not confirmed here.
A scheduled advisory committee discussion is not a decision, and a PCAC recommendation for inclusion would not be an approval. It would not make BPC-157 a licensed medicine, would not establish efficacy for any indication, and would not by itself make the peptide legal to sell or use. It would mean pharmacists could compound it under section 503A. Vendor copy that presents any of this as FDA moving toward legalisation is describing something that did not happen.
What research use only means
BPC-157 is sold online labelled for research use only, and it is worth being precise about what that label does. It is a statement by the seller that the product is not being offered as a medicine for human use. It is a legal position, not a quality claim, and nothing about it verifies identity, purity, concentration or sterility.
Regulatory positions here moved twice in 2026 and could move again. Anything you read about BPC-157's legal status, including this page, should be checked against the current FDA record before it is treated as current.
The evidence, one row per claim
| Claim | Tier | Source |
|---|---|---|
| FDA placed BPC-157 on the Category 2 bulk substances list under section 503A, citing possible immunogenicity risk, peptide-related impurities and insufficient safety data. | established | FDA Category 2 bulk drug substances page (Internet Archive snapshot, content current as of 8 July 2025) |
| FDA updated its Category 2 list effective 22 April 2026, removing 12 substances after the nominators withdrew their nominations, including BPC-157, TB-500, MOTS-c, injectable GHK-Cu, Melanotan II, Semax and PEG-MGF. | established | FDA Category 2 bulk drug substances page (Internet Archive snapshot, content current as of 22 April 2026), with the withdrawal filings in regulations.gov docket FDA-2015-N-3534 |
| FDA scheduled a PCAC meeting for 23-24 July 2026 to consider BPC-157 (free base) and BPC-157 acetate for the 503A Bulks List; the meeting outcome is not confirmed. | weak evidence | Federal Register doc. 2026-07361, PCAC notice of meeting, Docket No. FDA-2025-N-6895, published 16 April 2026 (meeting outcome not confirmed against a primary source, 2026-08-23) |
| A PCAC recommendation for inclusion is not an approval and does not by itself make a peptide legal to sell or use. | established | Federal Register doc. 2026-07361, PCAC notice of meeting, Docket No. FDA-2025-N-6895 |
| BPC-157's research literature concerns tissue repair and gastrointestinal protection; it is not a weight-loss agent and no trial supports weight-loss use. | established | BSCG (verify claim of absence via PubMed search before publishing) |
Sources
- FDA Category 2 bulk drug substances page (Internet Archive snapshot, content current as of 8 July 2025)
- FDA Category 2 bulk drug substances page (Internet Archive snapshot, content current as of 22 April 2026), with the withdrawal filings in regulations.gov docket FDA-2015-N-3534
- Federal Register doc. 2026-07361, PCAC notice of meeting, Docket No. FDA-2025-N-6895, published 16 April 2026 (meeting outcome not confirmed against a primary source, 2026-08-23)
- BSCG (verify claim of absence via PubMed search before publishing)
Keep reading
- Peptides for Weight Loss: A Tiered Guide to What Is Approved, Pipeline, and Grey MarketThe triage page. Place any compound name into one of three tiers in seconds, with the best trial number and th
- Research-Chemical Peptides: 5-Amino-1MQ and the Grey MarketThe consumer-protection page, built around the cleanest example of a compound with everything except human evi
- Growth Hormone Peptides and Fat Loss: Tesamorelin, Ipamorelin, CJC-1295, AOD-9604Four compounds, one shared mechanism story, and one shared evidence problem.